FOR IMMEDIATE RELEASE
DULUTH, GA – September 6, 2017
In early 2017, Boehringer Ingelheim (BI) acquired Merial, becoming the leader in equine health. As we have begun work to create the new Boehringer Ingelheim, an opportunity to leverage the knowledge and expertise from both companies emerged, as did the responsibility to provide support and leadership for the entire equine industry. To illustrate that responsibility, BI is introducing its new brand platform: Unbridle Your Potential. In short, BI provides health care products that will help unlock the potential in each horse.
Every BI brand plays a role in helping horses reach their potential. As the leading equine health company in the United States, BI recognizes that the community that cares for horses day in and day out requires products that are trusted to perform, allowing each horse to achieve its potential. Unbridle Your Potential is about bringing out the best in everyone – veterinarians, horse owners, trainers and the horses we all love.
The Boehringer Ingelheim equine portfolio consists of:
· GastroGard® (omeprazole) and UlcerGard® (omeprazole)
· Vaccines including Vetera® and Calvenza®
· A joint health portfolio that includes Legend® (hyaluronate sodium) Injectable Solution, Hyvisc® (hyaluronate sodium), Hyalovet® (hyaluronate sodium), Vetalog® Parenteral (triamcinolone acetonide injectable suspension), Surpass®(1% diclofenac sodium) and Equioxx® (firocoxib)
· Prascend® (pergolide tablets)
· Marquis® (15% w/w ponazuril)
· Zimecterin® Gold (ivermectin/praziquantel) and ZIMECTERIN (ivermectin)
“We’re excited about this new brand platform as it represents our leadership in the equine health industry and the understanding that everyone who cares for horses wants to see each animal do its best,” says Dave Gocken, species head of the U.S. Equine Business Unit, Boehringer Ingelheim.
“Whether it’s racing, performing, trail riding or any other number of activities, our products give everyone the opportunity to reach their potential. At its core, Unbridle Your Potential is about the passion people have in caring for their horses, and we’re pleased to help bring that passion to life with our leading product line-up.”
About Boehringer Ingelheim Animal Health
As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry’s top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
Vetalog and Surpass are registered trademarks of Boehringer Ingelheim Vetmedica, Inc.
Vetera, Calvenza and Prascend are registered trademarks of Boehringer Ingelheim Vetmedica GmbH.
GastroGard, UlcerGard, Legend, Equioxx, Marquis and Zimecterin are registered trademarks of Merial, Inc.
Hyalovet is a registered trademark of TRB Chemedica International S.A., Geneva Switzerland, used under license.
Hyvisc is a registered trademark of Anika Therapeutics, Inc., used under license.
©2017 Boehringer Ingelheim Vetmedica, Inc.
The National Reining Horse Association is not responsible for information contained in this press release. Please contact the author or submitting organization for further information, requests or questions.